Valtension comp. 160+12,5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

valtension comp. 160+12,5 mg filmovertrukne tabletter

teva b.v. - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 160+12,5 mg

Valteva comp. 160+12,5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

valteva comp. 160+12,5 mg filmovertrukne tabletter

teva b.v. - hydrochlorthiazid, valsartan - filmovertrukne tabletter - 160+12,5 mg

Dovprela (previously Pretomanid FGK) Den Europæiske Union - dansk - EMA (European Medicines Agency)

dovprela (previously pretomanid fgk)

mylan ire healthcare limited - pretomanid - tuberkulose, multidrugt-resistent - antimyco-bakterielle midler - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Teriflunomide Mylan Den Europæiske Union - dansk - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord Den Europæiske Union - dansk - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressants, selektiv immunosuppressive - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Qaialdo Den Europæiske Union - dansk - EMA (European Medicines Agency)

qaialdo

nova laboratories ireland limited - spironolacton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 og 5.